Genetics of Congenital Heart Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNationwide Children's Hospital

About this trial

Congenital heart disease (CHD) is the most common type of birth defect but the cause for the majority of cardiac birth defects remains unknown. Numerous epidemiologic studies have demonstrated evidence that genetic factors likely play a contributory, if not causative, role in CHD. While numerous genes have been identified by us and other investigators using traditional genetic approaches, these genes account for a minority of the non-syndromic CHDs. Therefore, we are now utilizing whole genome sequencing (WGS), with the addition of more traditional genetic techniques such as chromosomal microarray or traditional linkage analysis, to identify genetic causes of familial and isolated CHD. With WGS we are able to sequence all of the genetic material of an individual and apply different data analysis techniques based on whether we are analyzing a multiplex family or a cohort of trios (mother, father and child with CHD) with a specific isolated CHD. Therefore, WGS is a robust method for identification of novel genetic causes of CHD which will have important diagnostic and therapeutic consequences for these children.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects must have a diagnosis of Congenital Heart Disease or be related to individuals with Congenital Heart Disease.

Disqualifiers

Healthy individuals unrelated to those with Congenital Heart Disease

Trial population

cardiology clinic sample, community sample

Trial design

Design model

Family-based

Time perspective

Prospective

Treatments tested in this trial

  • Blood Sample Collection

    Other intervention

    Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.

Treatment groups

5,000 Participants
are divided into 1 treatment group
Group A: Study Subjects1 intervention

Trial outcomes

Primary outcomes

1

Identification of novel genetic contributors to congenital heart defects

Novel genetic abnormalities that are found to be associated with congenital heart defects in humans

Time frame
up to 3 years, from date of genetic analysis to completion of genetic data analysis or identification of novel genetic contributors, whichever comes first

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nationwide Children's Hospital

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator